Dubai, UAE, Singapore, March 31, 2017
Takeda Pharmaceuticals Company Limited (“Takeda”),announced today that Ricardo Marek has been appointed as the President of the Emerging Markets Business Unit (EMBU), based in Singapore, effective April 1, 2017. In his new role he will lead allbusiness operations across five geographic Areas that compriseEM BU – Asia Pacific (excluding Japan), China, Latin America, Middle East & Africa and Russia-CIS. Marekwill also serve as a Corporate Officer and member of Takeda’s Executive Team, and report to Christophe Weber, President and Chief Executive Officer of Takeda.
After joining Takeda in 2011, Ricardo became President of Takeda Brazil in 2013. He then took-on additional,concurrentresponsibilities, as Area Head ofLatin America (LatAm) in 2014.Ricardo will be relocating from his home in São Paulo, Brazil, to Singapore and succeeds Giles Platford who has moved to Zurich as President of Europe and Canada, also effective April 1, 2017.
“The Emerging Markets is one of Takeda’s core growth drivers.Ricardo’s success in delivering solid growth in Latin America over the last six years, coupled with his strong leadership skills and commercial acumen makes him well placed to lead this business unit,” commented Christophe Weber, President &CEO ofTakeda. “Ricardo has an impressive track-record spanning over 15 years in leadership positions. I am confident he will continue to lead our teams to great success in their work to deliverbetter health and a brighter future to patients.”
Marek’s experience also includes completing strategic acquisitions for Takeda across LatAm as well as launching the Oncology business in that part of the world for some of Takeda’s potentially life-saving and life-transforming medicines. His commitment to his employees and the development of talent has resulted in the countries under his remit being recognized with external awards from both the Great Place to Work® and Top Employer® Institutes. He holds an MBA from the University of São Paulo, Brazil.
-Ends-
Advertisement
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.
About Takeda’sEmerging Markets Business Unit
Headquartered in Singapore, Takeda’s Emerging Markets Business Unit (EM BU) is committed to bringing to patients its established, high-quality medicines, along with Takeda’s innovative portfolio. As one of the Company’s global growth drivers, it is primarily focused on the therapy areas of gastroenterology and oncology, and has a presence in 35 countries across five diverse geographic Areas: Asia Pacific (excluding Japan), China, Latin America, Middle East & Africa and Russia-CIS Takeda’s EM BU is also exploring collaborations to expand access to its medicines and address unmet patient needs. Its teams aspire to be viewed as ‘Best-in-Class’ in the eyes of patients, customers and its own employees. Takeda has been externally certified as ‘Top Employer’ in 20 countries of its geographic region by the Top Employer ® Institute.
© Press Release 2017
© Copyright Zawya. All Rights Reserved.
